Tangent Medical has received FDA 510(k) clearance for the NovaCath Secure IV Catheter System.

The closed IV catheter design integrates advanced catheter stabilisation, next-generation tubing management, passive needle encapsulation and blood control on every short-peripheral IV start.

Tangent Medical sales and marketing vice president Curtis Bloch said up to half of all short-peripheral IV catheters develop complications, which NovaCath has been designed to address.

"Our research with clinicians has validated there is nothing like it in the market. FDA clearance will pave the way for us to advance the safety and efficacy of IV therapy," Bloch said.

The NovaCath Secure IV Catheter System is designed to exceed the highest CDC, OSHA and INS standards for IV catheter stabilisation, according to Tangent.

The device’s passive needle shielding technology and closed system design are expected to reduce the risk of needlestick injuries and occupational exposure to blood to the lowest feasible extent.

Tangent Medical CEO and chairman Jeff Williams said; "Clinicians were quick to point out the novel design and benefits it would bring the practice of IV therapy, as well as patient and clinician safety."

Image: NovaCath Secure IV Catheter System Cleared by FDA. Photo: Tangent Medical.